Bryan Davis, DO
Endocrinology, Diabetes & Metabolism · Sewell, NJNPI 1639425754
Payments from drug & device makers
Across 646 payments — averaging $133.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$47K
- AstraZeneca$31K
- Novo Nordisk$2K
- Abbott$921
- Medtronic$726
- Amneal Pharmaceuticals LLC$717
- plus $5K from 34 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 131 | $46,551 |
| AstraZeneca | 89 | $31,158 |
| Novo Nordisk | 97 | $1,547 |
| Abbott | 56 | $921 |
| Medtronic(2 entities) | 6 | $726 |
| Amneal Pharmaceuticals LLC | 44 | $717 |
| Boehringer Ingelheim | 21 | $465 |
| Corcept Therapeutics | 28 | $454 |
| Bayer | 10 | $336 |
| Amgen(2 entities) | 22 | $327 |
| Sanofi-aventis U.S. LLC | 9 | $293 |
| Recordati_rare_diseases_inc. | 18 | $271 |
| Insulet Corporation | 14 | $262 |
| Mannkind Corporation | 5 | $236 |
| Xeris Pharmaceuticals, Inc. | 12 | $229 |
| Tandem Diabetes Care, Inc. | 8 | $227 |
| Radius Health, Inc. | 13 | $222 |
| Zealand Pharma US, Inc. | 6 | $201 |
| Valeritas, Inc. | 1 | $143 |
| IBSA Pharma Inc. | 7 | $109 |
| Ascensia Diabetes Care US Inc. | 6 | $102 |
| Ascendis Pharma Endocrinology Inc | 5 | $89 |
| Madrigal Pharmaceuticals | 4 | $87 |
| Companion Medical, Inc. | 1 | $86 |
| BD | 1 | $78 |
| Tolmar, Inc. | 5 | $74 |
| Kyowa Kirin, Inc. | 4 | $64 |
| Dexcom, Inc. | 2 | $61 |
| RGH Enterprises LLC | 1 | $50 |
| Sequel Med Tech, LLC | 2 | $48 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $46 |
| Antares Pharma, Inc. | 2 | $41 |
| AbbVie | 3 | $40 |
| Pfizer | 3 | $40 |
| Cequr Corporation | 1 | $33 |
| Verity Pharmaceuticals Inc. | 2 | $29 |
| Ultragenyx Pharmaceutical Inc. | 1 | $18 |
| Lifescan, Inc. | 1 | $16 |
| Amphastar Pharmaceuticals, Inc. | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$86,423 in reported general payments places this provider in the 90th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.
See all endocrinology, diabetes & metabolism providers in New Jersey →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other endocrinology, diabetes & metabolism in Sewell
- Barry GertzRahway$903K
- Nawras MakhsidaRandolph$882K
- Marc SandbergFlemington$567K
- Joanne WaldstreicherNew Brunswick$441K
- Gregory BaroneCherry Hill$433K
- Taher ModarressiPennington$414K
- Navtika DesaiHillsborough$408K
- Atara SchultzTeaneck$357K
- Anthony CannonTurnersville$296K
- Sunil AsnaniBrick$295K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.